Previous 10 | Next 10 |
BMF-500, a novel 3 rd generation covalent inhibitor of fms-like tyrosine kinase 3 (FLT3), is the second investigational compound, discovered and developed by Biomea’s FUSION™ System, to advance to the clinic. Phase I study (COVALENT-103) of BMF-500 will examine its safety an...
2023-04-19 12:26:57 ET Biomea Fusion ( NASDAQ: BMEA ) shares added ~7% on Wednesday after announcing plans to disclose new data from its COVALENT-111 Phase 1/2 trial for its lead candidate BMF-219 targeted at type 2 diabetes. The clinical-stage biotech said new data from t...
New clinical data from COVALENT-111 will be featured during the Late-Breaking Poster Presentations at the Scientific Sessions Biomea to hold an investor and KOL event during the Scientific Sessions REDWOOD CITY, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Bio...
Abstract 473 highlights the dose dependent reduction of menin target genes in ex vivo chronic lymphocytic leukemia (CLL) patient samples treated with BMF-219, an investigational covalent inhibitor. BMF-219 showed greater potency and ability to achieve >98% growth inhibition in these CLL pa...
REDWOOD CITY, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of ...
2023-03-30 14:35:20 ET Shares of the clinical-stage biotech Biomea Fusion (NASDAQ: BMEA) have been on fire this week. Specifically, the pre-revenue biotech's stock gapped up by a stately 99.8% over the first three and a half days of trading this week, according to data provided ...
2023-03-30 05:21:59 ET Biomea Fusion ( NASDAQ: BMEA ) has priced its underwritten public offering of 5M shares to raise $150M in gross proceeds. The shares are being issued to public at $30 each. Underwriters have been granted a 30-day option to purchase up to an additiona...
REDWOOD CITY, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defin...
2023-03-29 07:13:03 ET After rising ~99% in the previous session, Biomea Fusion ( NASDAQ: BMEA ) dipped in the pre-market Wednesday after the clinical-stage biotech announced the launch of an underwritten public offering of $125M worth of its common stock. A decision to gr...
2023-03-29 07:08:53 ET Biomea Fusion ( NASDAQ: BMEA ) has commenced an underwritten public offering of $125M of common shares. Underwriters have a 30-day option to purchase up to an additional $18.75M of common shares. BMEA -2.5% premarket to $29.94 Source: Press...
News, Short Squeeze, Breakout and More Instantly...
2024-07-18 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-18 04:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA). Investors who purchased Biomea securities are encouraged to obtain additional information...